Sierra Summit Advisors LLC Invests $10.63 Million in Novo Nordisk A/S $NVO

Sierra Summit Advisors LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 208,905 shares of the company’s stock, valued at approximately $10,629,000. Novo Nordisk A/S accounts for approximately 1.6% of Sierra Summit Advisors LLC’s portfolio, making the stock its 23rd biggest holding.

A number of other institutional investors have also modified their holdings of the stock. Quotient Wealth Partners LLC increased its position in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after acquiring an additional 177 shares during the period. Certuity LLC increased its position in shares of Novo Nordisk A/S by 3.6% during the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares during the period. Oakworth Capital Inc. increased its position in shares of Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after acquiring an additional 182 shares during the period. True North Advisors LLC increased its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after acquiring an additional 199 shares during the period. Finally, Joel Isaacson & Co. LLC increased its position in shares of Novo Nordisk A/S by 1.0% during the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after acquiring an additional 200 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on NVO. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, March 10th. Finally, Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $45.07 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm’s 50 day moving average price is $40.05 and its 200-day moving average price is $46.51. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The company has a market cap of $201.23 billion, a PE ratio of 10.58, a P/E/G ratio of 3.94 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.47 EPS for the current fiscal year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deutsche Bank said Novo Nordisk remains cautiously optimistic on its key cagrisema obesity study, suggesting the upcoming RD11 readout could outperform the disappointing prior trial and potentially improve investor sentiment. Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
• Positive Sentiment: Recent Wegovy data showed strong weight-loss efficacy, better physical function, and favorable body-composition results, while oral Wegovy also compared well with Eli Lilly’s oral GLP-1 candidate on weight loss, tolerability, and patient preference. How New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment Story
• Positive Sentiment: Analysts at Erste Group raised FY2026 and FY2027 EPS estimates for Novo Nordisk, signaling slightly better earnings expectations and some underlying confidence in the business outlook.
• Positive Sentiment: Denmark’s 1.9% GDP growth was boosted by pharmaceutical strength linked to Novo Nordisk, underscoring the company’s continued importance and strength in its core market. Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth
• Neutral Sentiment: Novo Nordisk continues to advance additional obesity-maintenance and cagrilintide studies, which keeps its pipeline active but does not yet change the near-term earnings picture. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Neutral Sentiment: Novo Nordisk is also expanding beyond obesity through a Parkinson’s program transfer and other strategic moves, but these are longer-term developments with limited immediate stock impact. Novo Nordisk Expands Parkinson’s Bet With AI Partner And Upside Potential
• Negative Sentiment: Eli Lilly’s encouraging oral GLP-1 results highlight intensifying competition in the obesity-pill market, which could pressure Novo Nordisk’s future market share and pricing power. From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook (NVO)
• Negative Sentiment: Other competitors, including Viking Therapeutics, are also developing oral weight-loss pills, adding to the competitive overhang on Novo Nordisk’s GLP-1 franchise. Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics’ Pill Could Crash the Weight-Loss Party

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.